Awny Farajallah, MD, FACP’s Post

Where are we standing in bladder cancer treatment?👀 Bladder cancer is the 10th most diagnosed type of cancer and although survival rates are relatively good, they have a tendency to resurface. Oncology made significant strides over the past years and standards of care in bladder cancer are being redefined.🏥 From combination therapy to urea-powered nanorobots, delve into the progress in bladder cancer treatment in our latest article!⬇️ https://lnkd.in/dhTsaMvg #Cancer #BladderCancer #BladderHealth #CancerResearch #Biotech #Biopharma Johnson & Johnson | Nanobots Therapeutics | Bladder Cancer Advocacy Network | Bladder Cancer Canada | Fight Bladder Cancer

This year's ASCO meeting underscored what an exciting time this is for advancements in cancer research, and cancer medicine, and the important impact that this work has for patients with cancer. One of the driving themes of this meeting is the rapid evolution of Precision Oncology, with existing targeted therapies moving “up-stream” to early stage disease. This resulting in a direct impact on cure rates, along with an increasing number of biomarkers and associated druggable targets that are rapidly advancing the development of new cancer treatments.  RWD was a continuing topic at ASCO. An ever important tool in advancing therapies is the leveraging of RWD to support patient care, along with supporting regulatory submissions to the FDA. With regard to patient care, RWD can help assess the compliance with rapidly evolving patient care guidelines, showing the adoption rate of newly approved targeted therapies, and the testing rates for their respective companion diagnostics. RWD also allows for post-approval evaluation of safety and efficacy in the broader population, thus helping to address health care disparities, to include assessing the impact of social determinants of health. During this exciting time, we at Syapse continue to be dedicated to our health system and life science partners in lessening the burden of cancer for all populations. 

A Phase III clinical trial led by UK researchers has demonstrated the first successful combination of chemotherapy with a drug targeting cancer’s metabolism developed for malignant pleural mesothelioma (MPM) in two decades. Patients with the asbestos-induced disease currently have a poor prognosis, as it doesn't tend to cause any symptoms until it has reached an advanced stage. There are around 2,500 deaths from mesothelioma each year in the UK. The anti-cancer treatment combines the new drug ADI-PEG20 and traditional chemotherapy, and holds promise for improving the lives of patients with mesothelioma. The researchers also concluded that this innovative chemotherapy could benefit other types of cancer. Read more about the trial here: https://lnkd.in/gHWByVDB #lifesciences #cancertreatment #executivesearch

🎥 Exciting new video interview published in the Applied Clinical Trials Magazine   Marc Buyse, founder of One2Treat, and Sébastien Coppe, PhD, CEO, discuss transforming cancer care through a more patient-centered approach to treatment effect assessment. They emphasize the importance of evaluating the benefit-risk profile of treatments holistically, highlighting the need to balance efficacy with safety to truly address patient needs and improve their overall experience.   They also mention FDA's Project Optimus, which aims to better identify the optimal dose of cancer treatments. This aligns closely with One2Treat's solution, which allows for a comprehensive evaluation of both the benefits and risks of different treatment doses, ensuring that we prioritize what truly matters to patients.   Discover how this patient-centered approach is paving the way for more compassionate and effective cancer care. Watch the full video here: https://lnkd.in/egdJ3uYi   #CancerCare #PatientCentricity #ClinicalResearch

Adenocarcinoma of the Lung: What patients should know about American Cancer Society National Cancer Institute (NCI) American Society of Clinical Oncology (ASCO) LUNGevity Foundation Canadian Cancer Society Johns Hopkins Medicine Cancer Research Institute (CRI) American Lung Association #Cancer #LCSM #LungAdenocarcinoma #CancerAwareness #PatientInformation #OncoDaily #Oncology

The longstanding one-size-fits-all mentality of measuring efficacy in oncology trials does not always account for the varied experiences of people living with cancer. Awny Farajallah, MD, FACP, Chief Medical Officer, says that as cancer continues to evolve, so should our approach to measuring patient outcomes. Read why it's time to rethink clinical trials in STAT: https://lnkd.in/gf-FZzvH

According to JAMA Oncology, cancer deaths increased by 21% from 2010 to 2019, amounting to 10 million worldwide. Explore 3 innovative advances that are revolutionizing cancer treatment: Precision #oncology: Tailoring therapy to a patient's unique tumor DNA signature leads to better outcomes and fewer side effects than standard treatments. AI-based cancer identification: #AI applications aid in risk assessment, early diagnosis, prognosis estimation, and treatment selection, often exceeding the accuracy of clinicians. Jab, a seven-minute cancer treatment: Approved for the administration of atezolizumab, this injection replaces time-consuming intravenous procedures, improving the patient experience.  Learn more: https://lnkd.in/dAx-x5wx In addition, ELEM's #digitaltwin accelerates drug development by simulating treatments such as Jab on virtual populations.  Contact us at [email protected] for a demo and explore the benefits of our virtual humans! #FDA #clinicaltrials #drugsafety

Revolutionary Cancer Treatments: How Antibody-Drug Conjugates Are Changing the Game for Breast Cancer Patients #13billion #advancementsinADCtechnologies #antibodydrugconjugates #breastcancer #CAGR #cancertreatments #clinicaltrials #COVID19pandemic #globalmarket #ImmunoGen #pharmaceuticalcompanies #Polivy #Roche #SeattleGenetics #targetedtherapies #traditionalchemotherapy

Combining Enfortumab-vedotin with Pembrolizumab to treat bladder cancer gives a better result than standard care used since the 1980s.... "Thomas Powles’s breakthrough success in treating a deadly bladder cancer could herald the next wave of powerful immunotherapeutic drugs." #bladdercancer #immunotherapy #ADC #enfortumabvedotin #pembrolizumab https://lnkd.in/eu8hie9m

The integration of combination therapy for Chronic Lymphocytic Leukemia (CLL) stands as a beacon of hope in cancer treatment. Recent data highlight significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to traditional chemoimmunotherapy. For patients, this translates to fewer treatment interruptions, a reduced risk of drug resistance, and minimized long-term side effects—marking a transformative shift in the cancer journey. As we continue to harness AI-driven insights and real-world evidence, the future of cancer treatment promises not just improved patient care, but an enhanced quality of life. This is the new frontier of personalized cancer care—where cutting-edge research meets compassionate healing. An insightful article by Alexandra Gerlach. #CancerCare #AIinCancerCare #CLLResearch #CombinationTherapy #PatientOutcomes